Literature DB >> 21952252

Advances in the management of sepsis and the understanding of key immunologic defects.

Lee P Skrupky1, Paul W Kerby, Richard S Hotchkiss.   

Abstract

Anesthesiologists are increasingly confronting the difficult problem of caring for patients with sepsis in the operating room and in the intensive care unit. Sepsis occurs in more than 750,000 patients in the United States annually and is responsible for more than 210,000 deaths. Approximately 40% of all intensive care unit patients have sepsis on admission to the intensive care unit or experience sepsis during their stay in the intensive care unit. There have been significant advances in the understanding of the pathophysiology of the disorder and its treatment. Although deaths attributable to sepsis remain stubbornly high, new treatment algorithms have led to a reduction in overall mortality. Thus, it is important for anesthesiologists and critical care practitioners to be aware of these new therapeutic regimens. The goal of this review is to include practical points on important advances in the treatment of sepsis and provide a vision of future immunotherapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21952252      PMCID: PMC3433833          DOI: 10.1097/ALN.0b013e31823422e8

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  112 in total

Review 1.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

2.  Germs.

Authors:  L Thomas
Journal:  N Engl J Med       Date:  1972-09-14       Impact factor: 91.245

3.  Spleen depletion in neonatal sepsis and chorioamnionitis.

Authors:  Paolo Toti; Claudio De Felice; Rossella Occhini; Karin Schuerfeld; Michela Stumpo; Maria Carmela Epistolato; Rosella Vatti; Giuseppe Buonocore
Journal:  Am J Clin Pathol       Date:  2004-11       Impact factor: 2.493

4.  Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis.

Authors:  Otelo Rigato; Reinaldo Salomao
Journal:  Shock       Date:  2003-02       Impact factor: 3.454

5.  Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.

Authors:  Jose Garnacho-Montero; Jose Luis Garcia-Garmendia; Ana Barrero-Almodovar; Francisco J Jimenez-Jimenez; Carmen Perez-Paredes; Carlos Ortiz-Leyba
Journal:  Crit Care Med       Date:  2003-12       Impact factor: 7.598

6.  Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia.

Authors:  Anita W Rijneveld; Sandrine Florquin; Thomas Hartung; Peter Speelman; Tom van der Poll
Journal:  J Infect Dis       Date:  2003-07-09       Impact factor: 5.226

7.  Anti-tumor necrosis factor-alpha therapy during murine Klebsiella pneumoniae bacteremia: increased mortality in the absence of liver injury.

Authors:  Thomas A Moore; Helen Y Lau; Anna L Cogen; Christine L Monteleon; Theodore J Standiford
Journal:  Shock       Date:  2003-10       Impact factor: 3.454

Review 8.  Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.

Authors:  Mical Paul; Ishay Benuri-Silbiger; Karla Soares-Weiser; Leonard Leibovici
Journal:  BMJ       Date:  2004-03-02

Review 9.  The enigma of sepsis.

Authors:  Niels C Riedemann; Ren-Feng Guo; Peter A Ward
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

10.  Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection.

Authors:  Richard Malley; Philipp Henneke; Sarah C Morse; Michael J Cieslewicz; Marc Lipsitch; Claudette M Thompson; Evelyn Kurt-Jones; James C Paton; Michael R Wessels; Douglas T Golenbock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-04       Impact factor: 11.205

View more
  35 in total

1.  Artesunate interacts with the vitamin D receptor to reverse sepsis-induced immunosuppression in a mouse model via enhancing autophagy.

Authors:  Shenglan Shang; Jiaqi Wu; Xiaoli Li; Xin Liu; Pan Li; Chunli Zheng; Yonghua Wang; Songqing Liu; Jiang Zheng; Hong Zhou
Journal:  Br J Pharmacol       Date:  2020-07-06       Impact factor: 8.739

2.  Efficacy and safety of corticosteroids in immunocompetent patients with septic shock.

Authors:  Xin Lu; Wei Han; Yan-Xia Gao; Shi-Gong Guo; Shi-Yuan Yu; Xue-Zhong Yu; Hua-Dong Zhu; Yi Li
Journal:  World J Emerg Med       Date:  2021

3.  Combination therapy with thymosin alpha1 and dexamethasone helps mice survive sepsis.

Authors:  Xiao-song Xiang; Ning Li; Yun-zhao Zhao; Qiu-rong Li; Jie-shou Li
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

4.  Dysregulation in microRNA expression in peripheral blood mononuclear cells of sepsis patients is associated with immunopathology.

Authors:  Juhua Zhou; Hina Chaudhry; Yin Zhong; Mir Mustafa Ali; Linda A Perkins; William B Owens; Juan E Morales; Franklin R McGuire; Elizabeth E Zumbrun; Jiajia Zhang; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  Cytokine       Date:  2014-09-29       Impact factor: 3.861

5.  Endotoxin-induced lung alveolar cell injury causes brain cell damage.

Authors:  Raquel Rodríguez-González; Ángela Ramos-Nuez; José Luis Martín-Barrasa; Josefina López-Aguilar; Aurora Baluja; Julián Álvarez; Patricia R M Rocco; Paolo Pelosi; Jesús Villar
Journal:  Exp Biol Med (Maywood)       Date:  2014-08-18

Review 6.  Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis.

Authors:  Courtney P Rudick; David L Cornell; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2017-07-28       Impact factor: 4.473

Review 7.  Mechanisms of gut barrier failure in the pathogenesis of necrotizing enterocolitis: Toll-like receptors throw the switch.

Authors:  David J Hackam; Misty Good; Chhinder P Sodhi
Journal:  Semin Pediatr Surg       Date:  2013-05       Impact factor: 2.754

8.  Selective endothelin-A receptor blockade attenuates endotoxin-induced pulmonary hypertension and pulmonary vascular dysfunction.

Authors:  Brent M Toney; Amanda J Fisher; Marjorie Albrecht; Angelia D Lockett; Robert G Presson; Irina Petrache; Tim Lahm
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

9.  The key roles of complement and tissue factor in Escherichia coli-induced coagulation in human whole blood.

Authors:  A Landsem; H Fure; D Christiansen; E W Nielsen; B Østerud; T E Mollnes; O L Brekke
Journal:  Clin Exp Immunol       Date:  2015-08-02       Impact factor: 4.330

10.  The immune response: targets for the treatment of severe sepsis.

Authors:  Aline M Bernard; Gordon R Bernard
Journal:  Int J Inflam       Date:  2012-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.